Artículo de Revisión 113 NUEVAS TERAPIAS EN CARCINOMA HEPATOCELULAR - M. Garrido S. et al. (TERT) gene in hepatocellular carcinoma cells. PLoS One 2014; 9: e84931. 47.- Tao SF, Zhang CS, Guo XL, Xu Y, Zhang SS, Song JR, et al. Anti-tumor effect of 5-aza-2’-deoxycytidine by inhibiting telomerase activity in hepatocellular carcinoma cells. World J Gastroenterol 2012; 18: 2334-43. 48.- Lin WH, Yeh SH, Yang WJ, Yeh KH, Fujiwara T, Nii A, et al. Telomerasespecific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice. Int J Cancer 2013; 132: 1451-62. 49.- Giovannini C, Gramantieri L, Chieco P, Minguzzi M, Lago F, Pianetti S, et al. Selective ablation of Notch3 in HCC enhances doxorubicin’s death promoting effect by a p53 dependent mechanism. J Hepatol 2009; 50: 969-79. 50.- Patil MA, Zhang J, Ho C, Cheung ST, Fan ST, Chen X. Hedgehog signaling in human hepatocellular carcinoma. Cancer Biol Ther 2006; 5: 111-7. 51.- Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009; 16: 425-38. 52.- Herencia C, Martínez-Moreno JM, Herrera C, Corrales F, Santiago-Mora R, Espejo I, et al. Nuclear translocation of β-catenin during mesenchymal stem cells differentiation into hepatocytesis associated with a tumoral phenotype. PLoS One 2012; 7: e34656. 53.- Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007; 117: 2713-22. 54.- Hato T, Goyal L, Greten TF, Duda DG, Zhu AX. Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions. Hepatology 2014; 60: 1776-82. 55.- Varela M, Castaño-Fernández O, Garrido M, Blanco-García L, Martínez-Camblor P, Mesa-Álvarez A, et al. Time to Progression of AFP (TPA) as a Predictor of Survival in Hepatocellular Carcinoma Treated with Sorafenib (SOR). J Cancer Ther 2014; 5: 1332-43. Gastroenterol. latinoam 2016; Vol 27, Nº 2: 106-113
gastro 2 2016
To see the actual publication please follow the link above